Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
U. Greinert, R. Hörster, C. Hoffmann, A. Strassburg, J. Welling, M. Ernst, C. Lange (Borstel, Hamburg, Germany). Successful treatment of rhodococcal pneumonia in advanced HIV-infection. Eur Respir J 2009; 34: Suppl. 53, 2467

Member's Comments

No comment yet.

Related content which might interest you: Disseminated bacterial community-acquired pneumonia in patients at late stages of HIV infection Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Corticosteroids as adjunctive therapy in tuberculosis pneumonia with ART Source: Breathe 2008; 5: 274 Year: 2009 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Telithromycin is effective in the treatment of high-risk patients with community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002 Efferent therapy in complex treatment of community-acquired pneumonia in patients with immunosuppression Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019 Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Appropriateness and delay to initiate therapy in ventilator-associated pneumonia Source: Eur Respir J 2006; 27: 158-164 Year: 2006 Invasive respiratory aspergillosis is a treatable disease with early diagnosis and aggressive therapy Source: Eur Respir J 2006; 28: Suppl. 50, 310s Year: 2006 Early recurrence of pneumocystis jiroveci pneumonia (PCP) in two HIV-infected patients: linking infection relapse and immune reconstitution syndrome Source: Annual Congress 2007 - Pulmonary infections in the immunocompetent and immunocompromised host Year: 2007 Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006 Hospital-acquired pneumonia in patients receiving immunosuppressive therapy Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017